The word “cosmeceutical” is widely used in marketing, product development, and consumer communication. It is often intended to describe cosmetic products that appear to deliver therapeutic or medical-like benefits. However, from a regulatory standpoint, the term cosmeceutical has no legal meaning under US FDA law.
Understanding how the US FDA views the term “cosmeceutical” is critical for cosmetic brands. Misuse of this word, or the claims associated with it, can cause a product to be reclassified as a drug, triggering serious compliance obligations and enforcement risks.
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), product classification and claim compliance have become even more important.
XPRO America is a professional US FDA Consultancy helping cosmetic brands correctly interpret regulatory definitions, evaluate claims, and maintain compliance.
What Does “Cosmeceutical” Mean in Practice
The term “cosmeceutical” is a marketing concept, not a regulatory category.
It is commonly used to suggest that a product:
- Beautifies the skin (cosmetic function)
- Also delivers advanced performance or active benefits
However, the US FDA recognizes only two relevant legal categories:
- Cosmetic
- Drug
There is no third category called cosmeceutical under US law.
How US FDA Defines a Cosmetic
A cosmetic is intended to:
- Cleanse
- Beautify
- Promote attractiveness
- Alter appearance
Examples:
- Moisturizers
- Cleansers
- Makeup
- Perfumes
- Shampoos
Cosmetic claims focus on appearance, not treatment or cure.
How US FDA Defines a Drug
A drug is intended to:
- Diagnose, cure, mitigate, treat, or prevent disease
- Affect the structure or function of the body
Examples:
- Acne treatments
- Hair growth products
- Skin lightening treatments
- Anti-dandruff treatments
If a product makes drug-type claims, it is regulated as a drug regardless of marketing terminology.
Why “Cosmeceutical” Creates Compliance Risk
Many brands use the word cosmeceutical to imply biological or therapeutic activity.
Examples of risky implied claims:
- “Stimulates collagen production”
- “Repairs damaged skin cells”
- “Heals acne”
- “Reverses aging at the cellular level”
These statements suggest drug intent.
Even if the label says “cosmeceutical,” the US FDA evaluates what the product claims to do, not what the company calls it.
Cosmeceutical Products Are Either Cosmetics or Drugs
From a regulatory perspective:
- If claims relate only to appearance → Cosmetic
- If claims relate to treatment or physiological action → Drug
- If both → Combination product
The word cosmeceutical does not change classification.
MoCRA and Product Classification
MoCRA strengthens US FDA authority to:
- Review labels and marketing claims
- Access substantiation records
- Mandate recalls of misbranded products
- Take enforcement action faster
Products marketed as cosmeceuticals with drug-type claims face increased enforcement risk.
Claims Drive Everything
US FDA determines classification based on:
- Label text
- Website content
- Advertising
- Social media posts
- Instructions for use
- Testimonials
If any of these imply drug intent, the product may be regulated as a drug.
Ingredient-Based Claims and Cosmeceuticals
Certain ingredient claims can imply drug action:
- Retinoids
- Salicylic acid for acne
- Minoxidil
- Hydroquinone
When tied to treatment claims, these push products into drug territory.
XPRO America evaluates ingredient and claim combinations.
Can You Use the Term “Cosmeceutical”
Using the term itself is not automatically illegal, but it is high risk.
If “cosmeceutical” is used:
- Claims must still remain cosmetic in nature
- No drug claims may appear
- Marketing language must be carefully controlled
Many brands choose to avoid the term altogether.
Relationship to Safety Substantiation
Under MoCRA, cosmetic products must maintain adequate safety substantiation.
If claims imply stronger biological activity, safety documentation must support that exposure scenario.
Claims and safety substantiation must align.
Import Implications
Products marketed as cosmeceuticals with drug-type claims may be:
- Detained at port
- Refused entry
- Placed on import alert
Pre-export claim review is essential.
Best Practices for Cosmeceutical Marketing
- Avoid disease-related terminology
- Focus on appearance-related benefits
- Avoid physiological mechanism claims
- Maintain substantiation for all claims
- Perform claim risk review
- Work with an experienced US FDA Consultancy
How XPRO America Supports Cosmeceutical Compliance
XPRO America operates as a trusted US FDA Consultancy providing:
- Cosmetic vs drug classification assessment
- Claim risk evaluation
- Label and marketing audits
- MoCRA compliance alignment
- Regulatory strategy consulting
For professional assistance, contact support@xproamerica.com.
Compliance Perspective
“Cosmeceutical” is a marketing word, not a legal category. Under US FDA authority and MoCRA enforcement, products are regulated strictly as cosmetics, drugs, or combination products based on their claims and intended use.
With expert guidance from XPRO America, cosmetic brands can position high-performance products safely within cosmetic boundaries and avoid unintended drug classification.
Leave a Reply